Q-omics provides the consensus-scored FAM83F profile across patient tissues and cancer cell-line models. FAM83F expression is associated with patient survival in 21 of 34 cancer types, with the highest sampling consensus in READ. Among the 18 cancer types available for tumor–normal comparison, FAM83F is differentially expressed in 11, with the highest sampling consensus in KIRP. Additionally, FAM83F protein abundance shows 20,566 significant protein co-abundance associations, with the highest sampling consensus in LSCC. Together, these results highlight READ, KIRP, and LSCC as cancer lineages where FAM83F shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for FAM83F — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes FAM83F survival associations across molecular data types. FAM83F RNA expression shows survival associations in the most cancer types (21), followed by mutation status (3) and mass-spec protein abundance (8). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible FAM83F RNA expression–survival associations across cancer types. High FAM83F expression shows unfavorable associations in ACC and LUAD, but favorable associations in READ, SCLC, KIRC and KIRP. The READ Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify READ as the clearest survival context for FAM83F RNA expression.
This table summarizes FAM83F tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 11, while mass-spec protein shows differences in 9. The strongest signals are observed in KIRC for RNA and LSCC for protein.
This table ranks reproducible tumor–normal expression differences for FAM83F. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. FAM83F shows lower tumor expression in KIRP, KIRC and THCA and higher tumor expression in LUAD, LUSC and KICH. The KIRP box plot shows higher FAM83F RNA expression in normal versus tumor tissue (log2 FC = −2.182, t-test p < 0.001).
This table shows molecular features associated with FAM83F in patient tissues and cancer cell lines. In patient samples, FAM83F shows the broadest associations at the RNA and protein expression levels, with LSCC recurring as the lineage with the largest associated feature set. In cancer cell lines, FAM83F RNA and mutation anchors are most strongly linked to RNA-expression features, especially in PANCREAS, while CRISPR and shRNA rows add functional-dependency signals in LUNG_NSCLC_LUAD and LUNG_SCLC.
